FIG. 1A



Phase I Control: Individual % Body Weight Change
B: 4697
B: 12293
B: 14690
B: 34696
B: 25285 Eu
% Body Weight Change
Eu
IV
IM
Weeks

FIG. 1B



Phase I Treated: Individual % Body Weight Change
A: 4199
A: 8494
A: 12300 young
A: 41799 young
A: 52099 young
Young
% Body Weight Change
IV
IM
Weeks

FIG. 1C



Phase I: Mean Body Weight
A: Phase I Treated
B: Phase I Control
mean body weight
550
500
450
400
350
300
B: Control
A: Treated
IV
IM
0 1 2 3 4 5 6 7 8 9 10 55
Weeks

FIG. 1D



Phase I: % Mean Body Weight Change
A: Phase I Treated
B: Phase I Control
% mean body weight change
30
20
10
0
-10
A: Treated
**
p<0.01
B: Control
IV
IM
0 1 2 3 4 5 6 7 8 9 10 55
Weeks

FIG. 2A



Phase II Control: Individual % Body Weight Change
C: 2388
C: 9495
C: 15395
C: 21687
C: 30194
% Body Weight Change
25
20
15
10
5
0
-5
-10
-15
-20
-25
IV
IM
0 1 2 3 4 5 6 7 8 9 10 11 12 35 43
Weeks

FIG. 2B



Phase II Treated: Individual % Body Weight Change
D: 16288
D: 20289
D: 23484
D: 32486
D: 34188
D: 39192
% Body Weight Change
25
20
15
10
5
0
-5
-10
-15
-20
-25
IV
IM
0 1 2 3 4 5 6 7 8 9 10 11 12 35 43
Weeks

FIG. 2C



Phase II: Mean Body Weight
C: Phase II Control
D: Phase II Treated
mean body weight
550
500
450
400
IV
IM
D: Treated
C: Control
0 1 2 3 4 5 6 7 8 9 10 11 12 35/43
Weeks

FIG. 2D



Phase II: % Mean Body Weight Change
C: Phase II Control
D: Phase II Treated
% mean body weight change
25
20
15
10
5
0
-5
-10
-15
-20
-25
IV
IM
D: Treated
C: Control
0 1 2 3 4 5 6 7 8 9 10 11 12 35/43
Weeks

FIG. 3A



Phase I Diarrhea Score Control
34696
14690
25285 Dead
4697
12293
dead
Diarrhea Score
IV IM IM IM IM IM IM IM IM
Week

FIG. 3B



Phase I Diarrhea Score Treated
Diarrhea Score
IV IM IM IM IM IM IM IM IM
8494
4199
12300
41799
52099
Week

FIG. 3C



Phase I Mean Diarrhea Score
Mean Diarrhea Score
5
4
3
2
1
0
-2
0
2
4
6
8
10
Weeks
IV IM IM IM IM IM IM IM
A: Phase I Treated
B: Phase I Control
B
A

FIG. 3D



Phase I Mean Diarrhea Score % Change
Mean Diarrhea Score % Change
50
25
0
-25
-50
-2
0
2
4
6
8
10
Weeks
IV IM IM IM IM IM IM IM
A: Phase I Treated
B: Phase I Control
B
A

FIG. 4A



Diarrhea Score: Phase II Control
Diarrhea Score
Week
dead
IV
IM
2388
9495 Dead
15395
21687
30194

FIG. 4B



Diarrhea Score: Phase II Treated
Diarrhea Score
Week
dead
IV
IM
39192
23484
16288 Dead
20289
32486
34188

FIG. 4C



Phase II Mean Diarrhea Score
Mean Diarrhea Score
Phase II Control
Phase II Treated
C
D
IV
IM
Weeks

FIG. 4D



Phase II Mean Diarrhea Score % Change
Mean Diarrhea Score % Change
Phase II Control
Phase II Treated
C
D
IV
IM
Weeks

FIG. 5A



Phase I Activity Score Control
Activity Score
Weeks
4697
12293
14690
25285 Dead
34696
dead
IV
IM
0
1
2
3
4
-2
0
2
4
6
8
10
55

FIG. 5B



Phase I Activity Score Treated
Activity Score
Weeks
4199
8494
12300
41799
52099
IV
IM
0
1
2
3
4
-2
0
2
4
6
8
10
55

FIG. 5C



Phase I Mean Activity Score
A: Phase I Treated
B: Phase I Control
Mean Activity Score
4
3
2
1
0
IV
IM
A B
-2
0
2
4
6
8
10
55
Weeks

FIG. 5D



Phase I Mean Activity Score % Change
A: Phase I Treated
B: Phase I Control
Mean Activity Score % Change
25
0
-25
-50
-75
IV
IM
B
A
-2
0
2
4
6
8
10
55
Weeks

FIG. 6A



Phase II Activity Control
2388
9495 Dead
15395
21687
30194
dead
dead
IV
IM
Activity Score
Weeks
4
3
2
1
0
-2
0
2
4
6
8
10
12
35

FIG. 6B



Phase II Activity Treated
16288 Dead
20289
23484
32486
34188
39192
dead
dead
IV
IM
Activity Score
Weeks
4
3
2
1
0
-2
0
2
4
6
8
10
12
35

FIG. 6C



Phase II Mean Activity Score
C: Phase II Control
D: Phase II Treated
Mean Activity Score
4
3
2
1
0
C
D
IV
IM
-2
0
2
4
6
8
10
12
35
Weeks

FIG. 6D



Phase II Mean Activity Score % Change
C: Phase II Control
D: Phase II Treated
Mean Activity Score % Change
50
25
0
-25
-50
-75
-100
C
D
IV
IM
-2
0
2
4
6
8
10
12
35
Weeks

FIG. 7A



Phase I Chronicity Score Control
Chronicity Score
Weeks
dead
IV
IM
4697
12293
14690
25285 Dead
34696
0
1
2
3
4
-2
0
2
4
6
8
10
55

FIG. 7B



Phase I Chronicity Score Treated
Chronicity Score
Weeks
IV
IM
4199
8494
12300
41799
52099
0
1
2
3
4
-2
0
2
4
6
8
10
55

FIG. 7C



Phase I Mean Chronicity Score
A: Phase I Treated
B: Phase I Control
Mean Chronicity Score
4
3
2
1
0
IV
IM
-2
0
2
4
6
8
10
55
Weeks
A
B

FIG. 7D



Phase I Mean Chronicity Score % Change
A: Phase I Treated
B: Phase I Control
Mean Chronicity Score % Change
50
25
0
-25
-50
-75
IV
IM
-2
0
2
4
6
8
10
55
Weeks
A
B

FIG. 8A



Phase II Chronicity Control
Chronicity Score
Weeks
dead
dead
IV
IM
2388
9495
15395
21687
30194

FIG. 8B



Phase II Chronicity Treated
Chronicity Score
Weeks
dead
dead
IV
IM
16288 Dead
20289
23484
32486
34188
39192

FIG. 8C



Phase II Mean Chronicity Score
C: Phase II Control
D: Phase II Treated
Mean Chronicity Score
4
3
2
1
IV
IM
C
D
-2
0
2
4
6
8
10
12
35
Weeks

FIG. 8D



Phase II Mean Chronicity Score % Change
C: Phase II Control
D: Phase II Treated
Mean Chronicity Score % Change
75
50
25
0
-25
-50
IV
IM
C
D
-2
0
2
4
6
8
10
12
35
Weeks

FIG. 9A



Phase I Hyperplasia Score Control
4697
12293
14690
25285 Dead
34696
dead
Hyperplasia Score
IV
IM
Weeks
-2
0
2
4
6
8
10
55

FIG. 9B



Phase I Hyperplasia Score Treated
4199
8494
12300
41799
52099
Hyperplasia Score
IV
IM
Weeks
-2
0
2
4
6
8
10
55

FIG. 9C



Phase I Mean Hyperplasia Score
A: Phase I Treated
B: Phase I Control
Mean Hyperplasia Score
4
3
2
1
0
IV
IM
B
A
-2
0
2
4
6
8
10
55
Weeks

FIG. 9D



Phase I Mean Hyperplasia Score % Change
A: Phase I Treated
B: Phase I Control
Mean Hyperplasia Score % Change
50
25
0
-25
-50
-75
-100
IV
IM
B
A
-2
0
2
4
6
8
10
55
Weeks

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 12A





FIG. 12B





Phase II IFNAR Level
16288 Dead
20289
23484
32486
34188
39192
30194 mis-dosed
15395
2388
9495 Dead
21687
IV
IM
Normalized IFNAR Level
Week
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-1
0
1
2
3
4
5
6
7
8
9
10
11
12

FIG. 13

FIG. 14A

H3 – heavy chain variable region of CPI-1697

EVQLVESGGGLVQPGGSLRLSCAFSGFTLSTSGMGIGWVRQAPGKGLEWVA
HWWDDDKYYNPSLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCAR
NYYPYDAWFDYWGQGTLVTVS

FIG. 14B

K1 – light chain variable region of CPI-1697

DIQMTQSPSSLSASVGDRVTITCSASSSINSNHLHWYQQKPGKAPKLLIYRTSILASGVPSRF
SGSGSGTSFTLTISSLQPEDFATYYCQQGSNIPFTFGQGTKVEIKR